Clinical Trial Update: Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide [Phase 2]

View source ↗

Summary

Phase 2 trial assessing rolapitant as an antiemetic for chemo-radiation–induced nausea and vomiting in malignant glioma patients receiving radiotherapy and temo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemo-radiation Induced Nausea and Vomiting
• Malignant Glioma

Drugs mentioned

• Rolapitant (rolapitant)

Snippet

Sponsor: Duke University | Conditions: Chemo-radiation Induced Nausea and Vomiting | Phase 2 | Status: COMPLETED | Results posted: 2023-07-11